GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives Consensus Rating of “Hold” from Analysts

GoodRx Holdings, Inc. (NASDAQ:GDRX) has received an average rating of “Hold” from the fifteen brokerages that are covering the stock, MarketBeat reports. Three equities research analysts have rated the stock with a sell recommendation, seven have issued a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $3.8125.

Several equities research analysts recently weighed in on the stock. Citigroup upped their price objective on shares of GoodRx from $3.50 to $4.00 and gave the stock a “buy” rating in a research report on Thursday, May 14th. Wells Fargo & Company cut their price objective on shares of GoodRx from $7.00 to $3.50 and set an “overweight” rating for the company in a research report on Wednesday, March 4th. Mizuho dropped their target price on shares of GoodRx from $4.00 to $3.00 and set a “neutral” rating for the company in a report on Friday, February 27th. TD Cowen raised their price target on shares of GoodRx from $3.00 to $4.00 and gave the company a “buy” rating in a research note on Monday, May 11th. Finally, JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of GoodRx in a report on Friday, February 27th.

GoodRx Trading Down 1.7%

GDRX opened at $2.92 on Friday. GoodRx has a twelve month low of $1.77 and a twelve month high of $5.81. The company has a 50-day simple moving average of $2.36 and a 200 day simple moving average of $2.49. The company has a quick ratio of 1.47, a current ratio of 1.47 and a debt-to-equity ratio of 0.78. The stock has a market capitalization of $1.00 billion, a price-to-earnings ratio of 48.67, a P/E/G ratio of 1.87 and a beta of 1.54.

GoodRx (NASDAQ:GDRX) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $0.07 earnings per share for the quarter, hitting the consensus estimate of $0.07. GoodRx had a net margin of 2.61% and a return on equity of 7.90%. The business had revenue of $194.01 million during the quarter, compared to analysts’ expectations of $185.40 million. During the same quarter in the prior year, the business posted $0.09 earnings per share. GoodRx’s revenue was down 4.4% compared to the same quarter last year. Analysts predict that GoodRx will post 0.17 EPS for the current fiscal year.

Hedge Funds Weigh In On GoodRx

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Essential Partners LLC lifted its stake in GoodRx by 375.4% in the 1st quarter. Essential Partners LLC now owns 14,304 shares of the company’s stock valued at $28,000 after purchasing an additional 11,295 shares during the last quarter. Meridian Wealth Management LLC bought a new position in GoodRx in the 4th quarter valued at approximately $29,000. SG Americas Securities LLC bought a new position in GoodRx in the 1st quarter valued at approximately $29,000. Krilogy Financial LLC bought a new position in GoodRx in the 1st quarter valued at approximately $33,000. Finally, Quarry LP bought a new position in GoodRx in the 3rd quarter valued at approximately $33,000. Institutional investors own 63.77% of the company’s stock.

About GoodRx

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.